ALTIMMUNE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors Of The October 6Th Deadline In The Altimmune Class Action Lawsuit

If you purchased or acquired securities in Altimmune between August 10, 2023 and June 25, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

Click here to participate in the action.

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) --

What's Happening:

• Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Altimmune, Inc. (“Altimmune” or the“Company”) (NASDAQ:ALT) in the United States District Court for the District of Maryland, Southern Division on behalf of all persons and entities who purchased or otherwise acquired Altimmune securities between August 10, 2023 and June 25, 2025 , both dates inclusive (the“Class Period”).
• Investors have until October 6, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Allegation Details:

• According to the complaint, on June 26, 2025, Altimmune published a press release announcing topline results from the IMPACT Phase 2b MASH trial of Pemvidutide in the Treatment of MASH. While defendants had continuously provided inflated expectations ahead of these results, the analysis showed a pointed failure by the Company to achieve statistical significance in its analysis of the fibrosis reduction primary endpoint in its IMPACT Phase 2b MASH trial. In particular, while a positive trend in fibrosis improvement was observed, statistical significance was not met due to a higher-than-expected placebo response. When questioned about this concerning miss, defendants answered indifferently, attributing this result to the Phase 2 nature of the trial and stated that Altimmune was hoping for better results following the Phase 3 trial.
  
• Following this news, the price of Altimmune's common stock declined dramatically. From a closing market price of $7.71 per share on June 25, 2025, Altimmune's stock price fell to $3.61 per share on June 26, 2025, a decline of 53.2% in the span of just a single day.
  

Next Steps:

If you purchased or otherwise acquired Altimmune shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at ... , telephone at (212) 355-4648, or by filling out this contact form . There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit . Attorney advertising. Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn , X , and Facebook , and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X .

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
...

MENAFN24092025004107003653ID1110107428